Skip to main content
Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0360
-0.0040 (-10.00%)
Apr 28, 2026, 1:54 PM EST

Oncotelic Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2017
Period Ending
 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2017
Revenue
--0.07--
Upgrade
Gross Profit
--0.07--
Upgrade
Selling, General & Admin
2.980.380.574.855.47
Upgrade
Research & Development
0-0.060.763.66
Upgrade
Operating Expenses
2.990.380.635.619.13
Upgrade
Operating Income
-2.99-0.38-0.56-5.61-9.13
Upgrade
Interest Expense
-0.89-0.86-1.04-2.97-2
Upgrade
Other Non Operating Income (Expenses)
0.36-0.26-0.150.680.29
Upgrade
EBT Excluding Unusual Items
-3.51-1.49-1.76-7.91-10.84
Upgrade
Impairment of Goodwill
--3.2-6.08-4.11-
Upgrade
Gain (Loss) on Sale of Investments
365.35-0.01--
Upgrade
Gain (Loss) on Sale of Assets
---16.95-
Upgrade
Legal Settlements
-0.2----
Upgrade
Other Unusual Items
-1.06-0.09-0.37-0.260.32
Upgrade
Pretax Income
360.57-4.78-8.214.68-10.52
Upgrade
Income Tax Expense
111.55----
Upgrade
Earnings From Continuing Operations
249.02-4.78-8.214.68-10.52
Upgrade
Minority Interest in Earnings
0.250.260.30.421.13
Upgrade
Net Income
249.28-4.52-7.95.09-9.39
Upgrade
Net Income to Common
249.28-4.52-7.95.09-9.39
Upgrade
Shares Outstanding (Basic)
421404384384303
Upgrade
Shares Outstanding (Diluted)
421404384457303
Upgrade
Shares Change (YoY)
4.12%5.29%-16.01%50.89%244.02%
Upgrade
EPS (Basic)
0.59-0.01-0.020.01-0.03
Upgrade
EPS (Diluted)
0.59-0.01-0.020.01-0.03
Upgrade
Gross Margin
--100.00%--
Upgrade
Operating Margin
---806.96%--
Upgrade
Profit Margin
---11290.13%--
Upgrade
EBITDA
---0.55-5.6-9.06
Upgrade
D&A For EBITDA
--0.010.010.06
Upgrade
EBIT
-2.99-0.38-0.56-5.61-9.13
Upgrade
Effective Tax Rate
30.94%----
Upgrade
Revenue as Reported
--0.07--
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.